Gene Therapy: Page 5
-
Kincell spins out of cell therapy biotech, joining wave of manufacturing startups
The company is the latest to emerge with plans to make production of cell-based medicines easier for researchers and biotechs.
By Ben Fidler • July 26, 2023 -
Gene therapy biotech Kriya adds $150M in fresh funds
Led by Vivek Ramaswamy's brother, Kriya has now raised over $600 million to fund gene therapy research spanning ophthalmology, neurology and metabolic disease.
By Kristin Jensen • July 26, 2023 -
Explore the Trendline➔
iStock via Getty ImagesTrendlineGene Therapy
Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges.
By BioPharma Dive staff -
Editas names Biogen veteran as top scientist in latest executive change
Linda Burkly’s appointment follows the exit of CSO Mark Shearman, whose departure Editas announced alongside layoffs earlier this year.
By Gwendolyn Wu • July 24, 2023 -
Sponsored by Center for Breakthrough Medicines
Cell and gene therapy is coming of age
Outsourcing in the cell and gene therapy industry is booming and no longer considered just a “trend.”
July 24, 2023 -
A cancer biotech’s collapse gives Neurogene a path to Wall Street
The startup, a developer of gene therapies for brain diseases like Rett syndrome, will bypass an IPO by merging with struggling drugmaker Neoleukin.
By Delilah Alvarado • July 18, 2023 -
Avrobio halts gene therapy research and considers a sale
The decision to explore “strategic alternatives” comes about six weeks after the company sold its most advanced treatment to Novartis for nearly $90 million.
By Ned Pagliarulo • July 12, 2023 -
Astellas buys rights to 4D Molecular’s technology in latest gene therapy deal
The licensing agreement for the biotech’s viral vector platform follows recent Astellas agreements with Taysha Gene Therapies and Kate Therapeutics.
By Delilah Alvarado • July 10, 2023 -
Sponsored by Center for Breakthrough Medicines
Overcoming AAV manufacturing challenges
Overcome issues with AAV vector scalability and reproducibility. Enable a wider application of gene therapies in a cost-effective and sustainable way.
July 10, 2023 -
Pfizer backs CRISPR biotech Caribou in latest cell therapy investment
Five years after helping launch Allogene Therapeutics, Pfizer is backing another developer of “off-the-shelf” cell therapies in a deal that gives the drugmaker the chance to acquire a multiple myeloma treatment.
By Kristin Jensen • July 6, 2023 -
Sarepta sells FDA fast pass earned from Duchenne gene therapy approval
The deal enables Sarepta to quickly cash in on the clearance of Elevidys, with $102 million in new funds to help bankroll its drug research.
By Jonathan Gardner • July 5, 2023 -
With FDA approval in hand, BioMarin lays out plan to sell $2.9M gene therapy
The agency granted a long-awaited clearance last Thursday, but unexpected aspects of the hemophilia treatment’s label had some investors worried about its commercial prospects.
By Jacob Bell • June 30, 2023 -
BioMarin finally secures FDA approval of hemophilia gene therapy
After a prolonged journey, the medicine, known as Roctavian, is now cleared for certain patients with hemophilia A, the more common form of the rare bleeding disorder.
By Jacob Bell • June 29, 2023 -
With new data, Nkarta battles doubts facing ‘off-the-shelf’ cell therapies
Though a newer regimen showed promise in patients with acute myeloid leukemia, earlier remissions haven’t held up as well as the company hoped.
By Ben Fidler • June 27, 2023 -
Pfizer’s hemophilia B gene therapy inches closer to regulatory approval
The treatment could become Pfizer’s first marketed gene therapy, an area the pharma has poured significant resources into in recent years.
By Delilah Alvarado • June 27, 2023 -
Sarepta prices Duchenne gene therapy at $3.2M
The cost makes Sarepta’s treatment among the most expensive medicines in the world. But company executives said they don’t expect significant insurer pushback.
By Ben Fidler • June 22, 2023 -
First Duchenne gene therapy approved by FDA for young children
The approval of Elevidys was a milestone for research into the progressive and deadly disease. But the subsequent failure of a confirmatory trial has raised questions for the FDA.
By Ben Fidler • Updated June 22, 2023 -
UniQure stock tumbles on ‘confusing’ results for Huntington’s gene therapy
While patients appear to be doing better than historical data suggests, mixed results on other measures perplexed analysts and sent shares falling.
By Jacob Bell • June 21, 2023 -
Bluebird, playing catch-up, gets decision date for sickle cell gene therapy
The FDA will issue a decision on lovo-cel by Dec. 20, roughly two weeks after a verdict is expected on a rival treatment from Vertex and CRISPR Therapeutics.
By Kristin Jensen • June 21, 2023 -
State of Play
Cell and gene therapy manufacturing: the next generation of startups
Joining larger CDMOs like Lonza and Catalent, a new group of companies aims to capitalize on persistent bottlenecks in producing complex genetic treatments.
By Gwendolyn Wu • June 20, 2023 -
Sponsored by Center for Breakthrough Medicines
A right-first-time approach to development
Avoid costly delays, don't let development oversights derail your advanced therapy commercialization. Read the article.
June 20, 2023 -
Ferring, with manufacturing update, takes a step towards first gene therapy sales
The FDA has cleared Ferring’s planned scale-up process for its bladder cancer treatment Adstiladrin, which the company plans to make available in the U.S. later this year.
By Delilah Alvarado • June 13, 2023 -
AstraZeneca teams up with startup Quell, joining ‘Treg’ cell therapy hunt
The pharma is the latest large drugmaker to show interest in the emerging technology, following similar deals by Bristol Myers and Regeneron.
By Ben Fidler • June 9, 2023 -
Using twin viruses, startup AAVantgarde aims to extend gene therapy’s reach
The biotech has raised about $65 million to test two ways to deliver larger genes into the body, which could help gene therapy treat more diseases.
By Ben Fidler • June 6, 2023 -
Sponsored by Bio-Rad
Overcoming common pitfalls in lentiviral cell and gene therapies
See how ddPCR technology can take your lentiviral cell and gene therapies to the next level.
By Marwan Alsarraj • May 30, 2023 -
PTC lays off staff, fires CFO as neuromuscular drug study fails
The biotech is giving up on early-stage gene therapy research as part of a restructuring meant to cut costs and redirect resources toward therapies most likely to succeed.
By Kristin Jensen • May 24, 2023